Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiBARU
BARU
Oct 7, 2026
BARU
BARU
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Pasar Dibuka: May 5, 2026, 8:02 PM ET
Volume
$8,217Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$8,217Tanggal Berakhir
Oct 7, 2026Pasar Dibuka
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader consensus on Polymarket reflects a narrow 54% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot drug delivery platform by October 7, 2026, driven by the absence of a commercial licensing or technology transfer agreement despite an ongoing evaluation extended from October 2024 to match the deadline. The initial non-exclusive research pact allowed Lilly internal testing of SmartDepot—Peptron's ultrasonic spray-drying tech for long-acting peptide formulations like GLP-1 agonists—but December 2025's extension without commercialization sparked Peptron stock declines and doubts amid Lilly's pivot toward oral obesity drugs and massive U.S. manufacturing investments. Balancing optimism from joint auto-injector collaboration hints, key swing factors include Q2 2026 earnings disclosures or regulatory filings that could signal deal progress, potentially tipping odds if positive data emerges from evaluations.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan